Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Chemists first looked at pyrimidines in the late 1800s, but industrial focus didn’t spike until the middle of the 20th century. Scientists realized that adjusting certain rings, adding halogens like chlorine and tweaking propyl chains dramatically changed how these compounds behaved. In the wake of the antibiotic revolution, people started looking past just penicillin for pharmaceutical backbones, and pyrimidine analogues came under the microscope. By the 1980s, the development of selective synthesis methods, including halogenation and thiolation, unlocked new possibilities, and 4,6-dichloro-2-propylthiopyrimidine-5-amine earned a place in the expanding toolkit for drug design, especially as the pharmaceutical world moved away from broad-spectrum treatments to targeted therapies that demanded precision starting materials. Its journey from obscure chemical to USP, EP, BP grade raw material didn’t happen overnight. Manufacturers adapted their routes, improved purification steps, and addressed evolving quality standards, reflecting the grit and persistence typical of R&D labs chasing higher yield, lower cost, and safer outcomes.
This compound stands as a crystalline powder used as a key intermediate in several active pharmaceutical ingredients. Companies use it because its backbone supports various modifications and keeps reactions predictable. Many players in the contract manufacturing field rely on its stability during scale-up, and the choice to register under global pharmacopeia grades comes from strict demand for reproducibility and traceability. The structure—two chlorine atoms anchoring a pyrimidine ring, a propylthio group at the two-position, and an amine moiety at five—sets up a platform adaptable to further chemical transformation, yet robust during shipment and storage. Drug makers appreciate that this is not some boutique laboratory compound, but a substance available at scale and quality levels aligned with Western pharmacopeias, making it a useful ingredient in approvals for Europe, North America, and beyond.
Handling 4,6-dichloro-2-propylthiopyrimidine-5-amine every day means noticing the details: faintly off-white crystals, a faint aromatic odor, moderate melting point falling in line with similar amine derivatives. Solubility falls low in water but jumps substantially in acetone, dichloromethane, and other polar aprotic solvents—handy when downstream processes work better in organics. Thermal stability holds up during both storage and routine synthetic steps, with decomposition temperatures well above the range of most pharmaceutical reactions. The presence of two electron-withdrawing chlorines and the sulfur-bearing side arm tunes its reactivity; you get both nucleophilic and electrophilic sites. Chemical compatibility lines up well with a range of protective group strategies, making it suitable in multi-step syntheses for API pathways.
Reliable manufacturers ship pharma-grade material with certificates of analysis detailing purity levels above 98.5%, water content below 0.5%, and controlled residual solvents—consistent with BP, EP, and USP monographs. Impurity profiling draws from validated HPLC and GC methods, and batch records trace every step from raw feedstock to packaging. Labels carry batch numbers, shelf life dates, handling symbols, storage instructions (cool, dry, away from oxidizers), and transport compatibility for cold chain or ambient conditions. Regulatory expectations demand more than just a purity number. Trace metals, polymorphic forms, and particle size data come under scrutiny, since these can impact downstream synthesis in API manufacturing. The discipline here isn’t dreamy—every margin point matters, and even minor contamination threatens the bottom line of pharmaceutical operations.
Synthetic routes to make this compound typically start from commercially available dichloropyrimidine precursors. Chemists introduce the propylthio group by nucleophilic substitution, using sodium or potassium propylthiolate in polar solvents under inert atmosphere, followed by an amination at the five position with ammonia or ammonium salts. Control over order of operations, temperature ramping, and purification via crystallization or extraction distinguishes successful batches from costly scrap. Route scouting and process optimization play a central role—engineers adjust solvent systems, tweak reaction times, and run impurity trend analyses to harmonize quality with cost and scalability. Documentation rooted in decades of process chemistry experience guides modern producers, merging theoretical know-how with hands-on batches coming off the reactor floor.
This amine core welcomes transformations, making it a practical handle for chemists chasing new pharmacophores. Derivatization stems from the nucleophilic amine, as well as the possibilities at both halogen sites on the ring. Cross-coupling chemistry, oxidative modifications, and protective group installation tap the modular nature of the scaffold. For instance, Suzuki and Buchwald-Hartwig coupling strategies let teams add complex aromatic structures at precise positions. Alkylation at sulfur, diazotization at nitrogen, and selective reduction at the pyrimidine ring bring a range of medicinal leads within reach. Professionals get hands-on with this compound, running small to medium scale reactions in search of optimized analogues for cancer, inflammation, or anti-infective profiles.
Over time, chemical suppliers and patents have listed the product under various aliases, including 4,6-dichloro-2-propylsulfanylpyrimidin-5-amine, 2-Propylthio-4,6-dichloropyrimidine-5-amine, and in some supplier catalogs as DCPP-5-Amine. Regulatory databases list CAS and EC numbers for tracking, and custom labels in contract projects may reflect code names linked to proprietary APIs. Anyone sourcing this product for regulated manufacturing soon discovers that clarity in nomenclature and reference standards helps avoid procurement blunders and regulatory missteps.
Workplace exposure standards for this compound align with those for other halogenated pyrimidines. Operators don nitrile gloves, goggles, and lab coats, and air-handling systems filter dust and vapors. Material safety data sheets from reputable suppliers lay out first aid responses for spills, skin contact, or inhalation. Chronic exposure studies suggest low but possible risk of irritation or sensitization, putting emphasis on procedural training for routine transfers and weighing. Waste management routines demand proper segregation; solvents and contaminated wipes go in halogenated waste streams, and filtered vents reduce environmental impact. Transport regulations mirror those for other fine chemicals, with packaging that withstands bumps and protects against moisture ingress. Operators depend on a culture of near-miss reporting and continuous review of incident logs to adjust protocols and uphold operational integrity.
Demand for this compound comes straight from the pharmaceutical sector, especially as a critical starting point for antihypertensive, antiviral, or antifungal active ingredients. Medicinal chemists adapt its versatile scaffold to plug into strategies for targeting specific kinase pathways or metabolic enzymes. Patent literature in the past decade features analogues made from this base in both blockbuster and orphan drug research. Outside finished drug synthesis, some agrochemical developers have explored similar structures for crop protection agents, but clinical research keeps most of the supply spoken for. Chemical biology teams tap its reactivity to build probe molecules for cell-based screening campaigns. Procurement teams, facing regulatory audits, often favor multi-sourced material from GMP-inspected plants, keeping supply chain risks as low as possible.
Laboratories focused on new drug discovery often return to this scaffold for fragment-based approaches. Advances in predictive modeling and in silico docking confirm why this molecule remains attractive—its rigidity and solubility make it a trusted site for attaching moieties with biological activity. Collaboration between commercial producers and academic labs seeded key advances in regioselectivity, enantioselectivity, and late-stage functionalization, all of which speed the jump from milligram proof-of-concept to kilogram preclinical supply. The latest R&D efforts jump well beyond classic amine derivatives; bioconjugation, fluorination, and linker chemistry use this molecule as a launch platform for next-generation drug conjugates. Data from these partnerships has delivered new reaction conditions, greener solvent choices, and time-saving analytical workflows, all fueled by pressure to funnel more candidates toward clinical trials on tighter timelines.
Regulatory submission files reference in vitro and in vivo assays testing for cytotoxic potential, mutagenicity, and bioaccumulation. Most studies report that the core molecule shows a low order of toxicity, but vigilance remains critical since downstream analogues may behave differently. Inhalation studies in rodents suggest the need for respiratory protection in bulk handling. Toxicology teams track both acute and chronic exposure endpoints, guiding safe work limits for factory technicians and pharmacy compounders. In the hands of experienced toxicologists, panels run by contract labs produce the data needed for REACH dossiers and global safety submissions, giving confidence that this intermediate will not trip hazard or environmental thresholds during normal operation. A strong safety culture relies not just on published data, but on near-miss event sharing, root cause analysis, and cross-training, all of which have kept industry incidents rare.
The pharma landscape keeps shifting toward higher-purity intermediates, stricter traceability, and novel routes to market. 4,6-dichloro-2-propylthiopyrimidine-5-amine holds relevance because medicinal chemists keep finding new ways to exploit the pyrimidine ring. Continuous flow synthesis and green chemistry protocols promise even higher yields with less waste, and digital batch control links real-time quality checks to global regulatory dashboards. The push for sustainable chemistry creates demand for cleaner routes and recycled solvents. Companies that invest in tech transfer and process intensification see not just higher margin but also faster regulatory sign-off. As automated labs crunch bigger chemical libraries, demand for high-spec intermediates like this will stick around, not because of nostalgia, but because innovation stacks up best on solid, trusted building blocks.
Anyone working in pharmaceutical formulation quickly learns to appreciate the small chemical tweaks that yield big effects. A molecule like 4,6-Dichloro-2-Propylthiopyrimidine-5-Amine might not have the name recognition of aspirin, but it earns its spot in the drug development toolbox. For reference, this compound carries the CAS number 96595-55-6.
The chemical structure is where the story starts. The core framework centers around a pyrimidine ring, a six-membered structure with nitrogen atoms at the 1- and 3-positions. At positions 4 and 6, chlorine atoms cling tightly to the ring, altering the electron distribution and physical interactions. The 2-position sports a propylthio group, which fans out hydrophobicity, shifting how the compound reacts in organic synthesis and mediates biologically relevant binding. The 5-position features an amino group, giving the molecule points for possible hydrogen bonding, which is crucial in drug-receptor interactions.
Structural features like these don’t just matter on paper. Over years in pharmaceutical labs, I’ve watched compounds dance through a gauntlet of analytical methods—HPLC for purity, NMR for checking substitution patterns, and melting point measurement for consistency. Slight alterations in substituent positions or elements like chlorine and sulfur often mean the difference between a useful intermediate and a waste of bench space.
Then there’s purity. Terms like BP, EP, and USP mean the material fits the strictest international pharmacopeia standards. Any scientist planning to use 4,6-Dichloro-2-Propylthiopyrimidine-5-Amine in pharmaceutical synthesis or as a research standard can’t afford contamination or structural ambiguity. I have seen pharmaceutical projects stall over discrepancies in raw material standards. Every lot comes with a certificate of analysis, and, wherever I’ve worked, nobody skips reading that document. Reliable sourcing with a known CAS number reduces risk, so teams don’t have to double-check identity or spend weeks on re-purification.
Working with compounds like 4,6-Dichloro-2-Propylthiopyrimidine-5-Amine isn’t about hoarding obscure chemicals; it’s about building blocks. This particular structure finds its way into synthesis of antiviral drugs and other critical treatments. The dichloro substitution pattern often increases metabolic stability, which means patients’ bodies won’t break down the medication too quickly. That can translate to more reliable dosing or reduced side effects.
The propylthio group gives medicinal chemists greater control over how the molecule behaves inside the body. Modifying side chains changes absorption rates, targeting, and interactions with proteins. The amino group lined up at the 5-position lets researchers plug the compound straight into further chemical reactions, creating more complex, effective molecules.
In practice, sourcing remains a headache. Lots that meet BP, EP, and USP standards aren’t always easy to secure, and prices fluctuate with availability of precursor chemicals. Over the years, I’ve seen research slow because of backorders or inconsistent specifications. To get around this, many pharma teams build stronger supplier relationships, test incoming batches with spectroscopy right away, and keep modest extra inventory when budgets allow.
Tight specifications can feel burdensome, but it actually pays off. Patients benefit from predictable and safe medications, regulators see fewer compliance issues, and research cycles move with more confidence. Clear chemical identity tied to a number like CAS 96595-55-6 streamlines communication between labs, suppliers, and regulators, which ultimately speeds up time-to-market for important therapies.
Growing up, I always thought every pill was just crushed-up magic. Years later, after working with several pharmacists and spending late nights reading industry papers, I learned how those neat white tablets owe a lot to compounds most people never hear about. One such compound stands out in the pharmaceutical manufacturing process—functioning as much more than a simple filler.
Pharmaceutical firms rely on versatile compounds to get the most out of every tablet, capsule, or injectable dose they produce. Take excipients for an example. Folks in research labs use these materials not just to bulk up a formulation, but to solve practical problems. They help address issues like powder flow, how fast a pill dissolves in your digestive system, and improving how stable a medicine stays on a pharmacy shelf. Imagine the headache of manufacturing pills that jam up expensive machinery because the mixture clumps together. Certain pharmaceutical compounds, such as microcrystalline cellulose or magnesium stearate, add consistency to the process and help ensure every dose a person swallows contains what it should—no more, no less.
I once spoke to a production manager who described how many batches had to be scrapped before they landed on the right combination of active drugs plus a reliable carrier. The wrong compound led to tablets that broke apart too soon, or refused to disintegrate at all. By using well-studied binders or disintegrants, manufacturers avoid costly recalls and frustrated patients.
Aside from patient safety, these compounds offer protection to the delicate drug molecules inside pills or capsules. Some drugs degrade fast if exposed to air, moisture, or light. Using the right protective coating or stabilizer ensures patients aren’t swallowing pills that have already lost their punch. Simple things like lactose, starch, or certain sugars wrap around the medicine to keep out unwelcome moisture, which means those medicines stay effective up to their labeled expiry date. The US Food and Drug Administration (FDA) keeps a close eye on how these inactive substances are used, reminding us there’s a clear link between what goes into manufacturing and end-user trust.
Ask any parent who gives their child crushed or chewed tablets—the taste can turn medicine into a battleground. Flavoring agents and sweeteners, often overlooked, shape the patient experience. Pharmaceutical companies experiment with different compounds to help mask bitterness, making medicines more acceptable for everyone from toddlers to older adults. Film coatings benefit those with trouble swallowing tablets by streamlining pill movement through the mouth and throat, cutting down on choking incidents.
Some compounds also help time how a drug is absorbed. Controlled-release formulas reduce the peaks and valleys in medication levels within the body, meaning fewer side effects and longer-lasting results. That impacts everything from antibiotics to long-term pain management treatments. These aren’t flashy improvements, but they do matter to people living with chronic conditions who need reliable, round-the-clock relief.
Supply chain hiccups and inconsistent quality still plague the industry. To tackle these issues, many leading manufacturers partner with certified suppliers focused on traceability and sustainability. More researchers are also exploring biobased and greener alternatives to traditional synthetic additives. Some plant-derived binders show promise, aiming to keep medicines both safe and more eco-conscious.
Transparency in labeling and public education could also use a boost. People deserve to understand not just what their medicine does, but what goes into it. Trusted pharmacists and medical professionals can bridge that gap, explaining why even something described as an “inactive” ingredient carries weight. The story of a drug, it turns out, begins long before it lands in a pill bottle—and depends on input from every scientist, technician, and production worker along the way.
Stepping into a pharmacy, reaching for a painkiller, most people never think about the checklists the product survives before they hold it. Quality in pharmaceuticals keeps people safe, plain and simple. Without clear standards, uncertainty creeps in. For pharmaceuticals, this means doctor’s trust dims, patient confidence drops, and health outcomes take a hit.
Three main pharmacopoeial standards guide the purity and quality debate—British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). Pharmaceutical companies depend on these manuals. They don’t just set purity targets. They carve out approved manufacturing routes, list acceptable impurity levels, dictate identification methods, and even weigh in on how storage should look.
These standards go far deeper than a label on a bottle. Each pharmacopoeia has detailed monographs—think recipes with exact ingredients and cooking steps for chemical and biological medicines. Like baking, changing a single instruction or skipping a quality check risks the whole batch.
Purity talks about more than the main ingredient. BP, EP, and USP spell out what shouldn’t wander into the final product as much as what must stay. Typical purity specification targets include:
Quality standards are living documents. Regulators rely on science, real clinical outcomes, toxicology, and real-world recall data to set impurity thresholds or tighten microbial rules. Scarier failures drive updates—nitrosamine impurity scandals in blood pressure drugs forced the EP and USP to act fast and review solvent handling rules. The best standards reward constant vigilance.
Supply chains reach around the globe. Raw materials come from one continent, get refined on another, tested at a third. Keeping this network honest demands more than trust. Manufacturers need in-house testing—high-performance liquid chromatography, gas chromatography–mass spectrometry—that can tell apart a trace impurity from the main ingredient, even in parts per million. Auditing suppliers regularly, being transparent about failures, and updating internal protocols keep the whole ecosystem safer.
Each time I’ve worked on quality review teams, we’ve caught problems that would have slipped through in laxer settings. Conversations with pharmacists show me that patients trust finished brands because they trust the barcode of the whole supply line.
Slipping on standards doesn’t just bend a rulebook. It risks real harm for real people. Pharmaceuticals rest on the discipline carved out by BP, EP, USP and the teams living by their rules. Raising the bar on testing, sharing failures, and toughening oversight deliver the kind of quality we all expect—and deserve.
Working with chemicals always brings responsibility, and 4,6-dichloro-2-propylthiopyrimidine-5-amine definitely deserves respect. With a structure containing chlorinated groups and sulfur, it falls into the category of organic compounds that can present serious hazards if ignored. My background in laboratory safety has shown me that such compounds often carry both short-term dangers—like skin or eye irritation—and longer-term risks, especially if handled carelessly or stored in the wrong conditions.
No chemical storage plan should start without looking at the temperature. Keeping this compound at room temperature in a tightly-sealed container works best. Glass bottles with PTFE-lined caps give a trustworthy seal and prevent reactions with the container material. Polyethylene or polypropylene containers sometimes risk slow degradation with chlorine-containing compounds, so glass stands out as the better option.
Direct sunlight and heat sources can kick off unwanted reactions or speed up slow decomposition. I always choose a cool, shaded cabinet specifically labeled for hazardous chemicals and separate from acids, alkalis, and oxidizing agents. Spill trays under containers serve as cheap insurance against accidental leaks.
Ventilated areas matter. Air circulation minimizes buildup of fumes that might irritate skin or lungs. Fume hoods give the highest level of control if the compound ever releases vapor or dust during handling.
My experience with lab work drilled the same message again and again: goggles, gloves, and long sleeves form your first barrier. Nitrile gloves withstand organic chemicals better than latex. I always double-check that there are no splits or holes before putting gloves on. Accidental splashes look unlikely—until they happen.
Face shields offer extra protection when measuring powders or working with liquid forms. A simple dust mask or, better yet, an N95 respirator add one more layer—especially if weighing out the compound or mixing it, since airborne particles push exposure up. Eye-wash stations and safety showers belong close by whenever you handle any chlorinated amines, since seconds matter in an emergency.
Cleanliness saves lives. Any surface contact gets cleaned up immediately using dedicated spill kits. Standard paper towels spread the chemical residue instead of containing it. Absorbent pads and neutralizing agents designed for organic spills take care of the job while protecting your skin from exposure.
Storage mistakes, like leaving containers unsealed or exposing them to sunlight, cause accidents or slow leaks. I’ve seen incidents where improper labeling led to confusion or mixing with incompatible substances. The fix starts with clear, bold labeling: chemical name, date received, hazard warnings. No busy lab can afford mystery bottles.
Training makes a difference. Every facility needs clear procedures on what to do in case of a spill, fire, or accidental contact. Teaching staff the why behind precautions—rather than giving them a checklist—builds a responsible safety culture. Less-experienced workers benefit from shadowing sessions so they don’t cut corners or make assumptions.
No business or lab ever wants negative headlines tied to poor chemical storage. Public safety and personal safety overlap, so systems that support both—like regular inspections and honest reporting of near-misses—save costs and reputations in the long run. I’ve learned that paying attention in the small moments, such as capping a bottle tightly or wiping up a spill right away, avoids the kind of disaster that makes the news.
Every person who works around chemicals like 4,6-dichloro-2-propylthiopyrimidine-5-amine carries the weight of that responsibility. Respect for the chemical, respect for co-workers, and respect for the community outside the lab—all these shape the choices made every day.
People often overlook how much impact packaging has on the day-to-day use of a material. I’ve worked in labs where a 1-kg jar lasts months, and on a production floor where only drums make sense. Both situations show why there’s no “one-size-fits-all” answer about package size.
Suppliers understand these differences. Smaller packs, like 100 g or 500 g, make sense for pilot work or academic labs. Once a method scales up, 5 kg and 20 kg bags start to make more financial sense, and then drums and supersacks take over. Sometimes a customer might want an unusual size, and the vendor can help with that — cost goes up, but so does flexibility. All sizes serve a purpose. The key detail: you pay for what you use, not waste sitting around. Shrinking waste matters for cash flow and for reducing compliance headaches.
If you care about trust, a Certificate of Analysis means everything. Years spent verifying supplier claims taught me that a strong CoA builds confidence, saves time, and keeps a project from going off the rails. A CoA gives you the measured facts: purity, moisture, trace metals, and anything else needed to meet a spec. Skipping it can lead to product failures or harsh surprises during audits.
Not every provider takes the same approach. Some attach a generic “sample” certificate. That never worked in my experience. Problems arise—batch-to-batch variation, undocumented changes, or unnoticed contamination. Reputable suppliers run tests on every batch, record results, and share that CoA each time. This step protects both the customer and the supplier; it turns vague promises into provable facts.
Pricing often drives buying decisions, but a rock-bottom deal without a real CoA and clear packaging options can result in bigger losses through inefficiency or failed lots. If a customer in pharma or electronics hears “no, there’s no CoA,” red flags go up fast. For many end users, regulatory compliance isn’t negotiable and the only way to demonstrate compliance lies in having that document in hand.
With the pressure from regulations such as ISO and cGMP growing, even companies outside those strictest fields now request batch-specific documentation. If a problem emerges—like a recall on a drug or a customer return for a tech part—the ability to pull up that batch’s CoA becomes priceless.
In my view, progress comes from tightening this supply chain link. Companies can set themselves apart by making their packaging and documentation as transparent as possible. Publish average lead times for odd container sizes, and spell out up front whether a CoA comes automatically or requires a request. If batch traceability includes QR codes or digital access to records, that’s even better.
Investing in documentation and thoughtful packaging makes life easier for everyone in the chain—chemist, purchasing manager, auditor, and ultimately the consumer. It’s about problem-solving, not red tape. The right size pack with a solid CoA gives customers the peace of mind they need to move forward, instead of always looking over their shoulders for the next mistake.
Chengguan District, Lanzhou, Gansu, China
